​

Agios Pharmaceuticals (AGIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AGIO Stock Forecast

Agios Pharmaceuticals (AGIO) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $53.50, with a high of $56.00 and a low of $51.00. This represents a 58.61% increase from the last price of $33.73.

$20 $28 $36 $44 $52 $60 High: $56 Avg: $53.5 Low: $51 Last Closed Price: $33.73

AGIO Stock Rating

Agios Pharmaceuticals stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (57.14%), 3 Hold (42.86%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 3 4 Strong Sell Sell Hold Buy Strong Buy

AGIO Forecast vs Benchmarks

TypeNameUpside
StockAgios Pharmaceuticals58.61%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-16
Avg Price Target-$51.00$52.67
Last Closing Price$33.73$33.73$33.73
Upside/Downside-51.20%56.15%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25333--9
Dec, 24433--10
Nov, 24463--13
Oct, 24463--13
Sep, 24363--12
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Danielle BrillRaymond James$51.00$44.4314.79%51.20%
Sep 27, 2024Andrew BerensLeerink Partners$56.00$45.6122.78%66.02%
Sep 10, 2024Chris RaymondRaymond James$56.00$44.0527.13%66.02%
Jun 17, 2024Chris RaymondRaymond James$55.00$43.4226.67%63.06%
Jun 03, 2024Gregory RenzaRBC Capital$53.00$44.2619.75%57.13%
May 28, 2024Chris RaymondRaymond James$45.00$38.3917.22%33.41%
Feb 03, 2023Piper Sandler$41.00$30.1835.85%21.55%
Dec 01, 2022J.P. Morgan$33.00$29.4612.02%-2.16%
Nov 17, 2022Goldman Sachs$32.00$27.1317.95%-5.13%
Apr 30, 2021Peter LawsonBarclays$70.00$55.8025.45%107.53%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024Raymond JamesOutperformOutperformhold
Oct 10, 2024RBC CapitalMarket PerformMarket Performhold
Sep 27, 2024Leerink PartnersMarket Performdowngrade
Sep 10, 2024Piper SandlerOverweightOverweighthold
Jun 03, 2024RBC CapitalOutperformOutperformhold
May 28, 2024Cowen & Co.BuyBuyhold
May 28, 2024Piper SandlerOverweightOverweighthold
Jun 27, 2023RBC CapitalOutperformOutperformhold
Feb 03, 2023Piper SandlerOverweightinitialise
Nov 17, 2022Goldman SachsSellNeutralupgrade

Financial Forecast

EPS Forecast

$-15 $-1 $13 $27 $41 $55 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.86$26.55$-1.36$-6.33-----
Avg Forecast$-4.67$25.51$-6.29$-6.26$11.44$-6.14$-5.11$-1.41$1.41
High Forecast$-9.32$18.11$-14.19$-6.60$10.51$-7.05$-7.30$-2.89$0.80
Low Forecast$-3.32$50.89$-4.02$-5.91$11.83$-3.30$-3.22$0.04$3.57
Surprise %4.07%4.08%-78.38%1.12%-----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$203.20M-$14.24M$26.82M-----
Avg Forecast$199.05M$558.82K$13.91M$27.72M$35.15M$95.27M$188.95M$463.37M$715.00M
High Forecast$154.59M$433.99K$10.06M$25.85M$34.01M$81.62M$185.43M$453.58M$477.00M
Low Forecast$351.32M$986.30K$27.36M$30.14M$36.47M$112.88M$192.48M$473.16M$1.56B
Surprise %2.08%-2.36%-3.23%-----

Net Income Forecast

$-5B $6B $17B $28B $39B $50B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-335.22M$1.60B$-74.56M$-352.09M-----
Avg Forecast$-341.28M$37.63B$-299.44M$-352.09M$621.74M$-366.33M$-324.03M$-114.12M$78.52M
High Forecast$-409.53M$30.03B$-359.33M$-422.51M$585.16M$-392.58M$-406.05M$-160.64M$44.54M
Low Forecast$-273.02M$45.23B$-239.56M$-281.67M$658.31M$-183.74M$-179.12M$2.43M$198.66M
Surprise %-1.78%-95.74%-75.10%------

AGIO Forecast FAQ

Is Agios Pharmaceuticals stock a buy?

Agios Pharmaceuticals stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Agios Pharmaceuticals is a favorable investment for most analysts.

What is Agios Pharmaceuticals's price target?

Agios Pharmaceuticals's price target, set by 7 Wall Street analysts, averages $53.5 over the next 12 months. The price target range spans from $51 at the low end to $56 at the high end, suggesting a potential 58.61% change from the previous close price of $33.73.

How does Agios Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

Agios Pharmaceuticals stock forecast shows a 58.61% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Agios Pharmaceuticals over the past three months?

  • January 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 40.00% Strong Buy, 30.00% Buy, 30.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 30.77% Strong Buy, 46.15% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.

What is Agios Pharmaceuticals’s EPS forecast?

Agios Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is 11.44 for 2024, a -280.73% decrease from the reported $-6.33 in 2023. The prediction for 2025 is $-6.14, $-5.11 for 2026, $-1.41 for 2027, and $1.41 for 2028.

What is Agios Pharmaceuticals’s revenue forecast?

Agios Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $35.15M for 2024, a 31.05% increase from the reported $26.82M in 2023. The forecast for 2025 is $95.27M, $188.95M for 2026, $463.37M for 2027, and $715M for 2028.

What is Agios Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, Agios Pharmaceuticals's average annual net income forecast is $621.74M for 2024, reflecting a -276.59% decrease from the reported $-352M in 2023. The projection for 2025 is $-366M, $-324M for 2026, $-114M for 2027, and $78.52M for 2028.